**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**  
**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**Date of report (Date of earliest event reported):** July 24, 2019

---

**IDEXX LABORATORIES, INC.**  
(Exact name of registrant as specified in its charter)

- **Delaware**  
  (State or other jurisdiction of incorporation)
- **000-19271**  
  (Commission File Number)
- **01-0393723**  
  (IRS Employer Identification No.)
- **One IDEXX Drive, Westbrook, Maine**  
  (Address of principal executive offices)
- **207.556.0300**  
  (Registrant's telephone number, including area code)
- **04092**  
  (ZIP Code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

---

**Securities registered pursuant to Section 12(b) of the Act:**  

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.10 par value per share</td>
<td>IDXX</td>
<td>NASDAQ Global Select Market</td>
</tr>
</tbody>
</table>
On July 24, 2019, Mr. Jonathan Ayers issued a statement addressing his medical condition resulting from a serious bicycling accident that occurred on June 27, 2019. A copy of that statement is furnished as Exhibit 99.1 to this Form 8-K and can be accessed in the Investor Relations section of the Company’s website at www.idexx.com. Information on the Company’s website does not constitute part of this Form 8-K.

This Form 8-K, and the document furnished with it, contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectation or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at www.sec.gov and via the Company’s website at www.idexx.com).

The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed.

99.1 Statement from Jon Ayers, dated July 24, 2019
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.

Date: July 24, 2019

By: /s/ Sharon E. Underberg

Sharon E. Underberg
Corporate Vice President,
General Counsel and Secretary
July 24, 2019

Statement from Jon Ayers:

As you know, I’ve been on medical leave since June 27th as a result of a serious bicycling accident, which occurred when riding with my regular early morning cycling group. I very much appreciate the well-wishes sent to me and my family over the past few weeks, and wanted to update you all on my condition.

As a result of the accident, I sustained a severe spinal cord injury. Fortunately, I did not sustain any head trauma or brain injury.

I am currently at a world-class spinal cord injury rehabilitation center, one of the very best in the country. Spinal cord injuries are highly complex and each case is unique. At present, I have limited arm and wrist movement/sensory and no mobility/sensory in my legs, torso and fingers.

With full time rehab, I expect to recover some neuromuscular capability, but the exact nature of any rehab is unique to the individual and injury. While I can’t put a precise timeline on my rehab process, based on the feedback I have received from my doctors and the rehab center staff, they currently expect my full-time rehab process to take three to five months. Fortunately I have a wonderful and supportive family with me, was in excellent physical condition prior to the accident, and received exceptional care in the weeks following the trauma.

Since the accident, I have remained in close contact with Larry Kingsley, our lead director, and the senior corporate management team at IDEXX. I have great confidence in Jay Mazelsky as Interim President and CEO; he knows our markets, technologies, and innovation processes well, and is deeply respected by our employees. Jay is also supported by our CFO, Brian McKeon, who has a track record of doing an outstanding job steering the company’s financial performance. Jay and Brian are joined by a phenomenal and deep management team, and a diverse and experienced board of directors. I remain dedicated to IDEXX’s Purpose to enhance the health and well-being of pets, people, and livestock, and I intend to return to IDEXX as soon as I’m able.

I would like to thank everyone at IDEXX for their dedication to our customers and our business. Our employees demonstrate a spirit of innovation and entrepreneurship, as well as a commitment to excellence, each and every day. I am proud of what we continue to achieve together as a team.

I am grateful for your support.

Sincerely,

Jon